John Patton, PhD
CEO and CHAIRMAN
John has extensive experience in Biotech industry startup. He co-founded Inhale/Nektar Therapeutics in 1990 after leading the drug delivery team at Genentech, founded Dance Biopharm (now Aerami Therapeutics) in 2009, co-founded InCarda in 2009, and iPHarma Limited in 2016.
Dominik Haudenschild, PhD
CoFounder, CSO and Director
Dominik is a Professor in the Department of Orthopaedic Surgery at UC Davis School of Medicine. His training is in the biochemistry and molecular biology of orthopaedic tissues, and his current research focuses on how early injury responses affect the disease trajectory of osteoarthritis
Jasper Yik, PhD
CoFounder, Sr. Scientist and Director
Jasper is a Molecular Biologist at UC Davis with over 18 years of advanced research experience in the regulation of gene expression that globally affects acute injury responses, inflammation, and osteoarthritis pathogenesis.
Erica pascal, Phd, jd
Head of IP Strategy
Erica is the founder of Ingensity™ IP, P.C., a provider of IP strategy for life sciences start-ups. Prior to the that, she was partner at DLA Piper. Erica began her career in gene expression, got her BS in biology from MIT, a Ph.D. in biochemistry and molecular biology from UC Berkeley, and a postdoc at the University of Illinois.
samantha miller, ms, mba
Corp Dev Advisor, Director
Samantha started her career as a scientist, and quickly found her passion for building new biopharma companies. She served as co-CEO of Cadence Health, CBO of InCarda and Dance Biopharm. She also led business development for Theravance, Nektar, Onyx, and values her early training at P&G Pharmaceuticals.
Mei-chang Kuo, PhD
Consulting Head of Pharmaceutics
Mei-chang has >35 years experience in start-up and mid-sized Biotech companies with an excellent track record of bringing new and lifecycle-
management products through different phases of research and development. He developed the formulation of Exubera (inhaled insulin) at Inhale/Nektar and cofounded iPharma Limited in 2016.
Art Tiption, phd
Consulting Head of Manufacturing
Art, a chemist and polymer scientist has extensive drug delivery commercialization experience. With significant roles at three drug delivery companies; including Founder and CEO, and President of two GMP PL/GA suppliers. Art is a past president and fellow of CRS, and a member of the National Academy of Inventors and the National Academy of Engineers.
Consulting Head of Quality and Compliance
>35 yrs in Operations, Quality, Regulatory Affairs, CMC. 16 yrs COO and CTO for Biopharm companies that developed drug/ device. Prior to this, 18 years for Johnson & Johnson as VP of Global Quality and Regulatory Affairs. Specialized in Due-Diligence, FDA consent decree mitigation, and Pre-Approval Inspection (PAI) readiness.
Christopher Rhodes, phd
Drug Product Contractor
Chris has extensive formulation and drug delivery experience and is the CEO of Drug Delivery Experts, which he founded in 2014. He played a key role in the development of Byetta and Bydureon (injectable and exenatide microsphere), Myalept (leptin protein), Afrezza (inhaled insulin), and Lusedra (propofol prodrug).
Ronald Wolff, PhD
Consulting Board Toxicologist
Ron has >30 years in nonclinical drug development with Lilly, Nektar, Novartis, and as a consultant for 8 years. He played key roles in development of Zyprexa (olanzapine), Movantik (pegylated naloxone), Tobi Podhaler (inhaled tobramycin), and Inbrija (inhaled levopdopa) and has overseen support for >30 INDs.
Michael Eldon, PhD
Clinical Pharm Consultant
Mike is the former Vice President of Clinical Pharmacology at Nektar Therapeutics, and a clinical pharmacology, pharmacokinetics/pharmacodynamics and pharmacometrics expert with >35 years of experience in the pharmaceutical industry. He is an Expert Consultant in the firm NDA Partners.
Robert Langer, phd
Bob, one of 11 Institute Professors at MIT, is a superstar in the development of drug delivery systems and pioneered the development of the first FDA approved PL/GA extended-release products. Bob has >1,500 articles, >325,000 citations; his h-index of 280 is the highest of any engineer in history and has >1,400 issued and pending patents
Lee Simon, md
Lee has served as the FDA’s Division Director of Analgesic, Anti-inflammatory and Ophthalmologic Drug Products, and on multiple FDA advisory committees and has extensive experience in drug development as a senior investigator for celecoxib in the US. Lee was a senior consultant to Pharmacia/Searle on COX-2 development.
Allan Green, PhD, JD
Allan is a physician, lawyer and scientist, with experience as an operating officer in the pharmaceutical industry. His legal practice focuses on the needs of FDA regulated industry. Dr. Green has successfully represented many American and Foreign clients in their relationships with the U.S. Food and Drug Administration (FDA).